Osteoporosis Market and Forecast Analysis

  • ID: 4238714
  • Report
  • 230 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Osteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in bone fragility results in osteoporosis patients being prone to sustaining fractures. Although the majority of osteoporosis patients are postmenopausal women, it is not a female-only disease. It is estimated that one in three women and one in five men aged over 50 years will sustain an osteoporosis-related fracture.

Market Snapshot
  • Prolia will drive growth of the US market, while Forteo losses will halt growth in Japan and the EU.
  • The oral bisphosphonate alendronate dominates the treatment of all severities of low bone mass.
  • Forecasted growth in the total prevalence of osteopenia and osteoporosis will be driven by aging populations.
  • Biosimilar erosion and new anabolic entrants with superior efficacy are set to erode Forteo’s blockbuster sales.
  • The arrival of Amgen’s Evenity will be delayed due to safety issues.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: OSTEOPOROSIS (Published on 31 May 2017)
OVERVIEW
EXECUTIVE SUMMARY
MARKET OVERVIEW AND TRENDS
MARKET DEFINITION AND METHODOLOGY
ACTONEL (RISEDRONATE)
BONIVA (IBANDRONATE)
DUAVEE ([CONJUGATED ESTROGENS + BAZEDOXIFENE])
EDIROL (ELDECALCITOL)
EVENITY (ROMOSOZUMAB)
EVISTA (RALOXIFENE)
FORTEO (TERIPARATIDE) AND MOVYMIA (TERIPARATIDE)
FOSAMAX (ALENDRONATE)
PROLIA (DENOSUMAB)
RECLAST (ZOLEDRONIC ACID)
TYMLOS (ABALOPARATIDE)
PRIMARY RESEARCH METHODOLOGY

TREATMENT: OSTEOPOROSIS (Published on 23 March 2017)
OVERVIEW
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS
TREATMENT TRENDS IN OSTEOPENIA
TREATMENT TRENDS IN OSTEOPOROSIS
TREATMENT TRENDS IN SEVERE OSTEOPOROSIS
COMPLIANCE RATES
UNMET NEEDS IN OSTEOPOROSIS

EPIDEMIOLOGY: OSTEOPOROSIS (Published on 23 February 2017)
OVERVIEW
EXECUTIVE SUMMARY
DISEASE BACKGROUND
SOURCES AND METHODOLOGY
FORECAST: OSTEOPENIA
FORECAST: OSTEOPOROSIS
EPIDEMIOLOGIST INSIGHT
STRENGTHS AND LIMITATIONS
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: OSTEOPOROSIS (Published on 09 March 2018)
OVERVIEW
PRODUCT OVERVIEW
BISPHOSPHONATES
ESTROGENS AND SERMS
CALCITONIN
ANABOLIC THERAPIES
OTHER DRUG CLASSES
PRODUCT PROFILE: FORTEO
PRODUCT PROFILE: PROLIA
PRODUCT PROFILE: TYMLOS

PIPELINE: OSTEOPOROSIS (Published on 09 March 2018)
OVERVIEW
CLINICAL PIPELINE OVERVIEW
COMPARATOR THERAPY
RECENTLY DISCONTINUED DRUGS
PRODUCT PROFILE (LATE STAGE): EVENITY

List of Figures
Figure 1: Osteoporosis drug sales across the US, Japan, and five major EU markets, by country, 2016-25
Figure 2: Osteoporosis sales in the US, by class, 2016-25
Figure 3: Osteoporosis sales for Edirol, generic eldecalcitol, Forteo, and Evenity in Japan, by product, 2016-25
Figure 4: Osteoporosis sales for Forteo, Movymia, biosimilar teriparatide, Evenity, and Tymlos across the US, Japan, and five major EU markets, 2016-25
Figure 5: Osteoporosis sales for branded and generic bisphosphonates across the US, Japan, and five major EU markets, 2016-25
Figure 6: Patient-based forecast methodology for osteoporosis
Figure 7: Price sources and calculations, by country
Figure 8: Actonel sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 9: Generic risedronate sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 10: Boniva sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 11: Generic ibandronate sales for osteoporosis across the US, Germany, Italy, Spain, and the UK, by country, 2016-25
Figure 12: Duavee sales for osteoporosis across the US and Italy, by country, 2016-25
Figure 13: Edirol sales for osteoporosis in Japan, 2016-25
Figure 14: Generic eldecalcitol sales for osteoporosis in Japan, 2016-25
Figure 15: Evenity sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 16: Evista sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 17: Forteo sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 18: Movymia sales for osteoporosis across the five major EU markets, by country, 2016-25
Figure 19: Biosimilar teriparatide sales for osteoporosis in the US, 2016-25
Figure 20: Fosamax sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 21: Generic alendronate sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 22: Prolia sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 23: Biosimilar denosumab sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 24: Reclast sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Figure 25: Tymlos sales for osteoporosis across the US and five major EU markets, by country, 2016-25
Figure 26: Percentage of patients with low bone mass diagnosed at each disease subtype for the US, Japan, and five major EU markets
Figure 27: Segmentation of patients suffering from low bone mass in the US, Japan, and five major EU markets, by disease severity and country
Figure 28: Percentage of patients receiving each line of therapy, by severity
Figure 29: Percentage of diagnosed patients receiving each type of therapy for the treatment of osteopenia, by country
Figure 30: Percentage of diagnosed patients receiving each class of pharmacological therapy for the first-line treatment of osteopenia, by country
Figure 31: Top three first-line treatment regimens for osteopenia patients, by country
Figure 32: Percentage of diagnosed patients receiving each type of therapy for the treatment of osteoporosis, by country
Figure 33: Percentage of diagnosed patients receiving each class of pharmacological therapy for the first-line treatment of osteoporosis, by country
Figure 34: Top three first-line treatment regimens for osteoporosis patients, by country
Figure 35: Top three second-line treatment regimens for osteoporosis patients, by country
Figure 36: Top three third-line treatment regimens for osteoporosis patients, by country
Figure 37: Top three first-line treatment regimens for severe osteoporosis patients, by country
Figure 38: Top three second-line treatment regimens for severe osteoporosis patients, by country
Figure 39: Percentage of diagnosed patients receiving each class of pharmacological therapy for the third-line treatment of severe osteoporosis, by country
Figure 40: Compliance rates of patients suffering from low bone mass in the US, Japan, and five major EU markets, by country and disease subtype
Figure 41: Key unmet needs in osteoporosis treatment across the US, Japan, and five major EU markets
Figure 42: Trend in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
Figure 43: Absolute change in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
Figure 44: Trend in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
Figure 45: Absolute change in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
Figure 46: Age-specific growth in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, 2016-36
Figure 47: Age-specific growth in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, 2016-36
Figure 48: Forteo for osteoporosis - SWOT analysis
Figure 49: Drug assessment summary of Forteo for osteoporosis
Figure 50: Drug assessment summary of Forteo for osteoporosis
Figure 51: Prolia for osteoporosis - SWOT analysis
Figure 52: Drug assessment summary of Prolia for osteoporosis
Figure 53: Drug assessment summary of Prolia for osteoporosis
Figure 54: Tymlos for osteoporosis - SWOT analysis
Figure 55: Drug assessment summary of Tymlos for osteoporosis
Figure 56: Drug assessment summary of Tymlos for osteoporosis
Figure 57: Evenity for osteoporosis - SWOT analysis
Figure 58: Drug assessment summary of Evenity for osteoporosis
Figure 59: Drug assessment summary of Evenity for osteoporosis

List of Tables
Table 1: Osteoporosis drug sales across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 2: Osteoporosis sales in the US, by brand and class ($m), 2016-25
Table 3: Osteoporosis sales in Japan, by brand and class ($m), 2016-25
Table 4: Osteoporosis sales in the five major EU markets, by brand and class ($m), 2016-25
Table 5: Summary of drug classes and molecules in the author’s osteoporosis patient-based forecast
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
Table 8: Estimated launch dates for key late-stage osteoporosis pipeline candidates in the US, Japan, and five major EU markets, by country, 2016-25
Table 9: Actonel sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 10: Generic risedronate sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 11: Boniva sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 12: Generic ibandronate sales for osteoporosis across the US, Germany, Italy, Spain, and the UK, by country ($m), 2016-25
Table 13: Duavee sales for osteoporosis across the US and Italy, by country ($m), 2016-25
Table 14: Edirol sales for osteoporosis in Japan ($m), 2016-25
Table 15: Generic eldecalcitol sales for osteoporosis in Japan ($m), 2016-25
Table 16: Evenity sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 17: Evista sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 18: Forteo sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 19: Movymia sales for osteoporosis across the five major EU markets, by country ($m), 2016-25
Table 20: Biosimilar teriparatide sales for osteoporosis in the US ($m), 2016-25
Table 21: Fosamax sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 22: Generic alendronate sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 23: Prolia sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 24: Biosimilar denosumab sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 25: Reclast sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 26: Tymlos sales for osteoporosis across the US and five major EU markets, by country ($m), 2016-25
Table 27: Physicians surveyed for the osteoporosis primary research study, 2016
Table 28: Physicians surveyed for the osteoporosis primary research study, 2016
Table 29: World Health Organization definitions of bone mass based on BMD
Table 30: Clinical risk factors included in FRAX scoring
Table 31: Selected bisphosphonates products for the treatment of osteoporosis across the US, Japan, and five major EU markets
Table 32: Selected SERMs and estrogen products for the treatment of osteoporosis across the US, Japan, and five major EU markets
Table 33: Calcitonin products for the treatment of osteoporosis across the US, Japan, and five major EU markets
Table 34: Other drugs available for the treatment of osteoporosis across the US, Japan, and five major EU markets
Table 35: Low bone mass patients treated with pharmacological therapy in the US, Japan, and five major EU markets, by country (%)
Table 36: Top three third-line treatment regimens for osteopenia patients, by country (%)
Table 37: Sources used for the epidemiological analysis of osteopenia and osteoporosis in the US, Japan, and five major EU markets, by country
Table 38: Sources not used for the epidemiological analysis of osteopenia and osteoporosis in the US, Japan, and five major EU markets, by country
Table 39: Total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
Table 40: Age-specific total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016
Table 41: Gender-specific total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016
Table 42: Total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
Table 43: Age-specific total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016
Table 44: Gender-specific total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016
Table 45: Key marketed drugs for osteoporosis
Table 46: Bisphosphonate class overview
Table 47: Estrogens/SERMs class overview
Table 48: Salmon calcitonin class overview
Table 49: Anabolic class overview
Table 50: Other drug classes overview
Table 51: Forteo drug profile
Table 52: Forteo pivotal trial data in osteoporosis
Table 53: Forteo late-phase trial data in osteoporosis
Table 54: Prolia drug profile
Table 55: Prolia pivotal trial data in osteoporosis
Table 56: Prolia late-phase trial data in osteoporosis
Table 57: Tymlos drug profile
Table 58: Tymlos Phase III trial data in osteoporosis
Table 59: Tymlos planned Phase III trials in osteoporosis
Table 60: Phase III pipeline products in development for osteoporosis
Table 61: Forteo drug profile
Table 62: Forteo trial data in osteoporosis
Table 63: Late-stage compounds that were recently discontinued for osteoporosis
Table 64: Odanacatib drug profile
Table 65: Odanacatib trial data in osteoporosis
Table 66: Evenity drug profile
Table 67: Evenity pivotal trial data in osteoporosis
Table 68: Evenity other late-phase trials in osteoporosis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll